Scientists have successfully tested an experimental blood thinner aptamer that provides potent anticoagulation and acts as an antidote to quickly reverse the side effects, especially bleeding.
The anticoagulant-antidote pair may have potential for patients with acute coronary syndrome and for those needing coronary revascularization. The anticoagulant aptamer Ch-9.3t specifically targets human coagulation factor IXa, which affects the initiation and propagation phases of coagulation. canadian antibiotics
Bolus injections of the 5-2C oligo-nucleotide antidote into anticoagulated animals rapidly reversed more than 95% of the anticoagulant effects of the apta-mer and restored hemostasis. It also prevented hemorrhage in the clipped tails of mice when given with Ch-9.3t.
The team’s findings were built on work published in 2002, in which they described a strategy for discovering antidote-controlled drugs and a first-version anticoagulant-antidote pair.
